[Skip to Content]
[Skip to Content Landing]
February 1993

Intraoperative Autotransfusion in Hepatic Resection for MalignancyIs It Safe?

Author Affiliations

From the Division of Surgical Oncology, Department of Surgery (Drs Zulim, Rocco, Goodnight, and Schneider), University of California, Davis Cancer Center and the University of California, Davis; the Department of Surgery, Kaiser North Medical Center, Sacramento, Calif (Dr Smith); and the Department of Surgery, University of Vermont Medical Center, Burlington (Dr Krag).

Arch Surg. 1993;128(2):206-211. doi:10.1001/archsurg.1993.01420140083013

• To evaluate whether intraoperative autologous transfusion increases the risk of hematogenous dissemination of tumor we reviewed the risk of lung metastasis as well as disease-free and long-term survival of patients who underwent resection of malignant hepatic neoplasms with this technique. A retrospective review of patients undergoing liver resection for malignant disease revealed 39 patients in whom intraoperative autologous transfusion was used. The 2-year actuarial survival in the patients in this series, as calculated with the Kaplan-Meier method, was predicted to be 75%. Two-year actuarial disease-free survival was predicted to be 28%, and the risk of developing lung metastasis at 3 years was estimated to be 40%. The predicted overall survival and risk of recurrence in this series compare favorably with published data for patients in whom intraoperative autologous transfusion was not used.

(Arch Surg. 1993;128:206-211)